PSI’s Director of Feasibility Research and Patient Recruitment Services, Kasia Moscicka, will present on Targeted Feasibility in Oncology Trials on Day 1, 29th November. She will share approaches to patient recruitment and retention, which are at the core of PSI’s operational strengths, discussing multifunctional approaches to feasibility assessments targeting specific patient populations across a variety of oncological indications and drug therapies. Case studies will be presented and discussed.
PSI will be fully represented at the event by operational experts to facilitate consultations and project-specific discussions.
About PSI CRO:
PSI is a privately-owned, full-service contract research organization (CRO), operating globally. PSI’s reputation on the market place is that of a no-nonsense CRO, capable of saving pharmaceutical sponsors millions of development dollars by consistently meeting clinical trial timelines. PSI’s global reach supports the operations of clinical trials across multiple countries and continents. PSI is known to be highly selective about the work that they pursue. PSI has exceptionally high repeat and referral business rates, while maintaining minimal staff turnover indicative of its commitment to be the best CRO in the world as measured by its customers and its employees. Global headquarters are located in Zug (Zürich), Switzerland at 113a Baarerstrasse 6300. www.psi-cro.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20161122005009/en/Business Wire
Last updated on: 22/11/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.